Latest News and Press Releases
Want to stay updated on the latest news?
-
REDWOOD CITY, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
Board of Directors has initiated search to identify successor Office of the President continues to perform the duties of President and CEO Perry Karsen appointed as Chairman of the Board REDWOOD...
-
Year-end 2017 Cash Balance of $103.1 Million Presentation of Clinical Data on Phase 1 programs expected in 2018 REDWOOD CITY, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals,...
-
REDWOOD CITY, Calif., Nov. 27, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...
-
REDWOOD CITY, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
-
Wholly-owned Immuno-oncology Candidate GITRL-Fc to enter clinic in 2H 2017 Q2 Cash Balance of $129.8M – Cash Through Q3 2019 Management to Host Conference Call/Webcast this afternoon at 4:30 p.m. ET...
-
REDWOOD CITY, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel...